A long-term phase 4 trial investigating Raxone for the treatment of Leber’s hereditary optic neuropathy met its primary endpoint, according to a press release from Santhera Pharmaceuticals.
LEROS is an externally controlled open-label intervention study intended to confirm the efficacy of Raxone (idebenone) in patients with Leber’s hereditary optic neuropathy (LHON) after 12 months. Additionally, the study is investigating long-term efficacy and safety data over 24 months.
The primary endpoint was the proportion of eyes to experience clinically relevant benefits after 12 months of